CGP-6809

CGP-6809 is an orally active DNA inhibitor. CGP-6809 exhibits antitumor activity against various transplantable tumors in mice and rats, including melanoma, prostate cancer, and rectal cancer. CGP-6809 can be used in research on various cancers, including melanoma, prostate cancer, and rectal cancer[1][2].

70457-70-4

12352005

DNA/RNA Synthesis

Cell Cycle/DNA Damage

Cancer

O=NN(C)C(NC[C@H]([C@]1([H])[C@@H]([C@H]([C@H](O1)OCC)O)OC)OC)=O

C12H23N3O7

321.33

[1]Schieweck K, et al. CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties. Cancer Chemother Pharmacol. 1989;23 (6) :341-7. |[2]Fiebig HH, et al. CGP 6809--a new nitrosoureido-sugar derivative with activity in human tumor xenografts. Cancer Chemother Pharmacol. 1989;23 (6) :337-40.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19018/

Reference compound1

No Development Reported